Congress approved an appropriations bill that makes FDA‑cleared multi‑cancer early detection (MCED) tests eligible for Medicare coverage beginning in 2029. The provision ties reimbursement to FDA approval and sets a starting fee equal to multi‑target stool DNA screening, with age‑phased eligibility that will expand annually. Industry stakeholders including Exact Sciences praised the change; the law sidesteps the longer US Preventive Services Task Force route and could materially expand market access for MCED developers.